ArticleCell host & microbe2007
CD8 T cell control of HSV reactivation from latency is abrogated by viral inhibition of MHC class I.
Article in Cell host & microbe, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- The immunogenicity of PRV ΔgE/TK/UL49.5 three-gene-deleted vaccine in mice.Virology journal · 2025Article
- The Host-Pathogen Interplay: A Tale of Two Stories within the Cornea and Posterior Segment.Microorganisms · 2023Review
- The Deletion of US3 Gene of Pseudorabies Virus (PRV) ΔgE/TK Strain Induces Increased Immunogenicity in Mice.Vaccines · 2022Article
- Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2.Communications biology · 2021Article
- Metagenomic Next-Generation Sequencing in the Diagnosis of HHV-1 Reactivation in a Critically Ill COVID-19 Patient: A Case Report.Frontiers in medicine · 2021Article
- T cell response kinetics determines neuroinfection outcomes during murine HSV infection.JCI insight · 2020Article
- Resolution of herpes simplex virus reactivation in vivo results in neuronal destruction.PLoS pathogens · 2020Article
- Increasing antigen presentation on HSV-1-infected cells increases lesion size but does not alter neural infection or latency.The Journal of general virology · 2018Article
- Review
- Establishment of HSV1 latency in immunodeficient mice facilitates efficient in vivo reactivation.PLoS pathogens · 2015Article
- Immunological control of herpes simplex virus infections.Journal of neurovirology · 2013Review
- Bovine Herpes Virus 1 (BHV-1) and Herpes Simplex Virus Type 1 (HSV-1) Promote Survival of Latently Infected Sensory Neurons, in Part by Inhibiting Apoptosis.Journal of cell death · 2013Review
- Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8⁺ T cell responses and protective immunity.PloS one · 2013Article
- A cultured affair: HSV latency and reactivation in neurons.Trends in microbiology · 2012Review
- The molecular basis of herpes simplex virus latency.FEMS microbiology reviews · 2012Review
- Control of HSV-1 latency in human trigeminal ganglia--current overview.Journal of neurovirology · 2011Review
- Illuminating viral infections in the nervous system.Nature reviews. Immunology · 2011Review
- Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.Journal of virology · 2011Article
- Delaying the expression of herpes simplex virus type 1 glycoprotein B (gB) to a true late gene alters neurovirulence and inhibits the gB-CD8+ T-cell response in the trigeminal ganglion.Journal of virology · 2010Article
- Persistent viral infection elevates central nervous system MHC class I through chronic production of interferons.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
In humans, herpes simplex virus (HSV) establishes latency in sensory nerve ganglia from where it periodically reactivates, whereas in murine models, the virus efficiently establishes latency but rarely reactivates. HSV inhibits MHC class I antigen presentation to CD8 T cells efficiently in humans but poorly in mice, and whether this is a crucial determinant of HSV's ability to reactivate in humans remains uncertain. To test this, we generated a panel of recombinant HSVs that inhibit presentation by murine MHC class I mimicking the effect in humans. Antigen-specific CD8 T cells prevent the in vivo reactivation of wild-type HSV. Despite their presence in the ganglia of latently infected mice, CD8 T cells do not prevent the reactivation of recombinant HSVs that inhibit murine MHC class I in mice. These findings suggest that efficient inhibition of MHC class I by HSV is a key factor in its ability to reactivate in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.